


Available at www.sciencedirect.com

ScienceDirect

journal homepage: www.elsevier.com/locate/hemonc

CASE REPORT

Clotrimazole troches induce supratherapeutic blood levels of sirolimus and tacrolimus in an allogeneic hematopoietic cell-transplant recipient resulting in acute kidney injury



Jessica El-Asmar^{a,b}, Rebecca Gonzalez^c, Ryan Bookout^c, Asmita Mishra^{a,d}, Mohamed A. Kharfan-Dabaja^{a,d,*}

^aDepartment of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center, Tampa, FL, USA

^bDepartment of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon

^cDepartment of Pharmacy, H. Lee Moffitt Cancer Center, Tampa, FL, USA

^dDepartment of Oncologic Sciences, H. Lee Moffitt Cancer Center/University of South Florida, Morsani College of Medicine, Tampa, FL, USA

Received 2 September 2015; accepted 15 November 2015
Available online 27 November 2015

KEYWORDS

Allogeneic hematopoietic cell transplantation;
Clotrimazole;
Sirolimus;
Tacrolimus

Abstract

Allogeneic hematopoietic cell transplantation is a potential curative treatment option for various malignant and nonmalignant hematologic disorders. Patients undergoing an allogeneic hematopoietic cell transplant are prescribed immune-suppressant therapies to facilitate hematopoietic donor-cell engraftment and prevent graft-versus-host disease. Drug–drug interactions may occur, owing to exposure to complex multidrug regimens with narrow therapeutic windows and high toxicity profiles. Here, we describe a unique case of a 65-year-old man with poor-risk acute myeloid leukemia who underwent a matched-sibling hematopoietic cell allograft. Sirolimus and tacrolimus were used for graft-versus-host disease prophylaxis. He developed oral thrush requiring treatment with clotrimazole troches, which subsequently resulted in serious renal toxicity attributed to supratherapeutic levels of sirolimus and tacrolimus. Patient renal function improved after temporarily holding both immune suppressants, and administering phenytoin to help induce sirolimus and tacrolimus metabolism. This case highlights sudden

* Corresponding author at: Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center, 12902 Magnolia Drive, FOB-3, Tampa, FL 33612, USA.

E-mail address: Mohamed.Kharfan-Dabaja@Moffitt.org (M.A. Kharfan-Dabaja).

and serious toxicities that resulted from clotrimazole–sirolimus and clotrimazole–tacrolimus drug–drug interactions, even when administered topically.

© 2015 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Allogeneic hematopoietic cell transplantation (allo-HCT) is a potential curative treatment option for various malignant and nonmalignant hematologic disorders [1–5]. Patients undergoing allo-HCT are prescribed immune suppressive therapies to facilitate hematopoietic donor-cell engraftment and prevent graft-versus-host disease (GVHD) [6]. For several years, the combination of a calcineurin inhibitor, namely cyclosporine, with methotrexate was the most commonly used regimen to prevent acute GVHD. Later, data showed a lower incidence of Grades 2–4 acute GVHD when using tacrolimus versus cyclosporine in unrelated donor allografting [7]. Combining tacrolimus with sirolimus has become a popular regimen for GVHD prophylaxis at various transplant programs worldwide, owing to a lower incidence of severe mucositis when compared to methotrexate [8–10].

During allo-HCT, it is imperative to maintain blood levels of immune suppressants within a desirable therapeutic range to ensure engraftment, prevent GVHD, and avoid drug-related toxicity and consequent morbidity [11]. Drug–drug interactions may occur as a result of exposure to medications with narrow therapeutic windows and high toxicity profiles. Understanding the mechanism(s) associated with metabolism of such drugs is important to help avoid unwanted and potentially serious drug–drug interactions [11].

Tacrolimus (FK506), a calcineurin inhibitor, is primarily metabolized by the CYP4503A4 system in the liver and intestinal wall, and is well-known for its inter- and inpatient pharmacokinetic variability [12]. Sirolimus, an inhibitor of the mammalian target of rapamycin (mTOR) enzyme, exerts its function by reducing DNA transcription and translation, and inducing cell cycle arrest in the G1 phase in activated lymphocytes, among others [11]. Similar to tacrolimus, sirolimus is predominantly metabolized by the hepatic CYP4503A4 [13,14].

Azole antifungal agents are CYP3A4 inhibitors commonly used in the setting of allo-HCT for anti-fungal prophylaxis and treatment of fungal infections [15–20]. Systemic triazoles, such as fluconazole, posaconazole, and voriconazole, are used consistently in allo-HCT patients to inhibit fungal cytochrome P450 14- α -sterol demethylase [21]. Drug–drug interactions with these agents are well documented for CYP3A4 inhibition, requiring dose reductions in other concomitant CYP3A4-substrate medications by 25–90%, depending on which azole antifungal is being prescribed [11]. Inhibition of CYP450 enzymes by azole antifungals primarily occurs through intestinal and hepatic CYP3A4. Conflicting data regarding inhibitory or inducing effects of oral clotrimazole exist between laboratory and human studies [21]. However, oral administration of a CYP3A4 substrate

in combination with clotrimazole may result in the inhibition of presystemic (intestinal) versus systemic (hepatic) metabolism by CYP3A4 [21].

Empiric dose-reduction of calcineurin inhibitors and sirolimus is necessary when azole antifungals are prescribed [11]. Vigilant monitoring of immunosuppressant blood levels is imperative to ensure therapeutic benefit and avoid toxicities. Several case reports have described renal toxicity occurring when combining azoles with calcineurin inhibitors or sirolimus [22–25]. The potential adverse drug–drug interaction between oral clotrimazole troches and tacrolimus was anecdotally described in a liver-transplant recipient [26]. Here, we present the first case, to our knowledge, of an allo-HCT recipient who developed acute kidney injury as a result of elevated levels of both sirolimus and tacrolimus following use of clotrimazole troches for treatment of oral thrush.

Case report

A 65-year-old man with poor-risk acute myeloid leukemia with associated complex karyotype underwent an allo-HCT in first complete remission from a human leukocyte antigen-matched-sibling donor (Class I: A–C; Class II: DRB1) using granulocyte-colony stimulating factor-mobilized peripheral blood stem cells. The HCT-comorbidity index of the patient at the time of transplantation was two [27]. The preparative regimen for allo-HCT consisted of 40 mg/m² intravenous fludarabine (Day –5, Day –4, Day –3, and Day –2) and 130 mg/m² intravenous busulfan aimed at a target area-under-the curve (AUC) dose of 3,500 mmol min/L per dose \times four doses (Day –5, Day –4, Day –3, and Day –2). GVHD prophylaxis consisted of tacrolimus started on Day –3 at a dose of 0.01 mg/kg (ideal body weight), given initially as a 24-hour continuous intravenous infusion and later converted to an oral formulation using a 1:4 ratio on Day +12 post-allografting. A 12-mg loading dose of sirolimus was given on Day –1, followed by 4 mg/d beginning on Day 0. The immunosuppressant-goal range for tacrolimus was \sim 3–7 ng/mL, and \sim 8–14 ng/mL for sirolimus. Antimicrobial prophylaxis consisted of 800 mg acyclovir orally twice a day, 400 mg ciprofloxacin orally twice a day, and 50 mg micafungin once daily, started on Day 0. The dose of infused CD34 cells was 9.41×10^6 /kg of recipient body weight. The clinical course of the patient was complicated by diarrhea associated with *Clostridium difficile*, which developed on Day –2 and required 125 mg vancomycin orally four times per day. On Day +9 post-transplantation, the patient developed oral mucositis, which progressed to Grade 3 by Day +12 and required intravenous hydromorphone for pain control. On Day +15, the patient had evidence of oral thrush. At that time, the oral mucositis had improved slightly, and there were no




Fig. 1 Tacrolimus level.




Fig. 2 Rapamycin (sirolimus).

ulcerative lesions on the oral mucosa or the tongue. The patient was prescribed 10 mg clotrimazole troches (Perrigo, Minneapolis, MN, USA) orally five times per day. By Day +17, there was near resolution of the thrush. By Day +18, it was noted that his serum sirolimus levels had increased by at least 2-fold (from 13.1 ng/mL to >30.0 ng/mL), and his tacrolimus levels had increased nearly four-fold (from 4.6 ng/mL to 17.2 ng/mL; Figs. 1 and 2). The serum creatinine level increased from a baseline of 0.7–1.2 mg/dL,

and reached a peak level of 3.2 mg/dL by Day +20 (Fig. 3). Sirolimus and tacrolimus doses were held on Day +18, and clotrimazole troches were discontinued at that time, although tacrolimus and sirolimus levels remained elevated (Figs. 1 and 2). Phenytoin (300 mg, orally) was administered on Day +20 and Day +23 to accelerate CYP3A4 metabolism of sirolimus and tacrolimus. By Day +24, the serum creatinine measurement in the patient had decreased to 2.3 mg/dL, and immunosuppressant levels normalized within




Fig. 3 Creatinine level.

therapeutic ranges (tacrolimus level decreased to 6.1 ng/mL, and the sirolimus level to 13.1 ng/mL). The patient also developed evidence of sinusoidal obstructive syndrome (SOS) on Day +25, requiring placement of an intraperitoneal shunt for management of ascites. During the period of supratherapeutic immunosuppressant levels and acute renal failure, the patient did not require hemodialysis and continues to recover well from the sequelae of SOS. Both tacrolimus and sirolimus were restarted on Day +27 at 0.5 mg daily and 1 mg daily, respectively.

Discussion

Recognition of clinically significant interactions with immunosuppressant therapy is essential to minimize toxicity and maximize therapeutic efficacy. Azole antifungals inhibit CYP3A4 and, accordingly, require major dosage modifications of immunosuppressants, such as sirolimus and tacrolimus. The systemic absorption of oral clotrimazole troches is highly variable and unpredictable, as noted by conflicting results of its inhibitory effects *in vitro* versus *in vivo*. In our case, using the Drug Interaction Probability Scale as published by Horn et al. [28], we demonstrated a probable drug interaction between clotrimazole troches and sirolimus or tacrolimus. The scores for each particular drug–drug interaction, namely clotrimazole troches-sirolimus and clotrimazole troches-tacrolimus, were seven and seven, respectively [28].

Shord et al [21] demonstrated the inhibitory effects of oral clotrimazole prescribed three times daily for five days, and administered with oral versus intravenous midazolam (a CYP3A4-surrogate probe) in a randomized open-label crossover study in healthy volunteers. Co-administration of a strong CYP3A4 substrate (midazolam) in combination with clotrimazole troches resulted in reduction of oral midazolam clearance by 40%, and a 40% increase in AUC [21].

Intravenous midazolam administration was unaffected. These data suggested that concomitant use of oral clotrimazole with an oral CYP3A4 substrate can substantially alter the bioavailability of such medications.

Unlike systemic triazoles, where interactions with immunosuppressants are well described, the impact of oral clotrimazole on the pharmacokinetics of these medications may be underestimated due to its low systemic concentration. Here, we demonstrated the potential clinical effects of clotrimazole troches on sirolimus and tacrolimus in an allo-HCT recipient who developed oral thrush. In this case, the patient developed supratherapeutic levels of tacrolimus and sirolimus within a short 3-day period, which resulted in serious, but reversible, acute kidney injury. Throughout the transplant procedure, the fluid balance of the patient was closely monitored and maintained with intravenous fluids as best as possible in a euvolemic state, hence making dehydration a less plausible cause of his renal failure. The patient received phenytoin to expedite the CYP3A4 metabolism of sirolimus and tacrolimus. Improvement of renal function did not occur until 1 week after clotrimazole was discontinued.

Our case highlights this potentially serious interaction between clotrimazole oral troches and systemic sirolimus and tacrolimus, and certainly the need for dose adjustment when utilizing these drugs concomitantly.

Conflicts of interest

The authors declare no conflicts of interest.

References

- [1] Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Mahfouz RA, Hamadani M. Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on

- hematopoietic cell transplantation. *Biol Blood Marrow Transplant* 2013;19:1006–12.
- [2] Ayala E, Figueroa J, Perkins J, Kim J, Yue B, Riches M, et al. Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma. *Clin Lymphoma Myeloma Leuk* 2015;15:335–40.
 - [3] Hamadani M, Mohty M, Kharfan-Dabaja MA. Reduced-intensity conditioning allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia. *Cancer Control* 2011;18:237–45.
 - [4] Ayas M, Nassar A, Hamidieh AA, Kharfan-Dabaja M, Othman TB, Elhaddad A, et al. Reduced intensity conditioning is effective for hematopoietic SCT in dyskeratosis congenita-related BM failure. *Bone Marrow Transplant* 2013;48:1168–72.
 - [5] Bacigalupo A, Socie G, Hamladji RM, Aljurf M, Maschan A, Kyrzcz-Krzemien S, et al. Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: an EBMT analysis. *Haematologica* 2015;100:696–702.
 - [6] Kharfan-Dabaja M, Mhaskar R, Reljic T, Pidala J, Perkins JB, Djulbegovic B, et al. Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation. *Cochrane Database Syst Rev* 2014;7:CD010280.
 - [7] Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. *Blood* 2000;96:2062–8.
 - [8] Pidala J, Kim J, Jim H, Kharfan-Dabaja MA, Nishihori T, Fernandez HF, et al. A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. *Haematologica* 2012;97:1882–9.
 - [9] Cutler C, Logan B, Nakamura R, Johnston L, Choi S, Porter D, et al. Tacrolimus/sirolimus versus tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. *Blood* 2014;124:1372–7.
 - [10] Nelson R, Shapiro JF, Perkins JB, Kim J, Nishihori T, Pidala J, et al. Sirolimus, tacrolimus and antithymocyte globulin as GVHD prophylaxis in HLA-mismatched unrelated donor hematopoietic cell transplantation: a single institution experience. *Bone Marrow Transplant* 2015;50:1487–9.
 - [11] Glotzbecker B, Duncan C, Alyea 3rd E, Campbell B, Soiffer R. Important drug interactions in hematopoietic stem cell transplantation: what every physician should know. *Biol Blood Marrow Transplant* 2012;18:989–1006.
 - [12] Fung JJ, Starzl TE. FK506 in solid organ transplantation. *Ther Drug Monit* 1995;17:592–5.
 - [13] Kuhn B, Jacobsen W, Christians U, Benet LZ, Kollman PA. Metabolism of sirolimus and its derivative everolimus by cytochrome P450 3A4: insights from docking, molecular dynamics, and quantum chemical calculations. *J Med Chem* 2001;44:2027–34.
 - [14] Gallant-Haidner HL, Trepanier DJ, Freitag DG, Yatscoff RW. Pharmacokinetics and metabolism of sirolimus. *Ther Drug Monit* 2000;22:31–5.
 - [15] Molina JR, Serrano J, Sanchez-Garcia J, Rodriguez-Villa A, Gomez P, Tallon D, et al. Voriconazole as primary antifungal prophylaxis in children undergoing allo-SCT. *Bone Marrow Transplant* 2012;47:562–7.
 - [16] Mauskopf J, Chirila C, Graham J, Gersten ID, Leather H, Maziarz RT, et al. Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants. *Am J Health Syst Pharm* 2013;70:1518–27.
 - [17] Gergis U, Markey K, Greene J, Kharfan-Dabaja M, Field T, Wetzstein G, et al. Voriconazole provides effective prophylaxis for invasive fungal infection in patients receiving glucocorticoid therapy for GVHD. *Bone Marrow Transplant* 2010;45:662–7.
 - [18] Cordonnier C, Rovira M, Maertens J, Cornely OA, Ljungman P, Einsele H, et al. Voriconazole as secondary antifungal prophylaxis in stem cell transplant recipients. *Haematologica* 2011;96:e9–10.
 - [19] Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Baden LR, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. *Blood* 2010;116:5111–8.
 - [20] Bandettini R, Castagnola E, Calvillo M, Micalizzi C, Ravegnani M, Pescetto L, et al. Voriconazole for cryptococcal meningitis in children with leukemia or receiving allogeneic hemopoietic stem cell transplant. *J Chemother* 2009;21:108–9.
 - [21] Shord SS, Chan LN, Camp JR, Vasquez EM, Jeong HY, Molokie RE, et al. Effects of oral clotrimazole troches on the pharmacokinetics of oral and intravenous midazolam. *Br J Clin Pharmacol* 2010;69:160–6.
 - [22] Daneshmend TK. Ketoconazole–cyclosporin interaction. *Lancet* 1982;2:1342–3.
 - [23] Ferguson RM, Sutherland DE, Simmons RL, Najarian JS. Ketoconazole, cyclosporin metabolism, and renal transplantation. *Lancet* 1982;2:882–3.
 - [24] Shepard JH, Canafax DM, Simmons RL, Najarian JS. Cyclosporine-ketoconazole: a potentially dangerous drug–drug interaction. *Clin Pharm* 1986;5:468.
 - [25] Kwan JT, Foxall PJ, Davidson DG, Bending MR, Eisinger AJ. Interaction of cyclosporin and itraconazole. *Lancet* 1987;2:282.
 - [26] Miesles L, Venkataramanan R, Yokoyama I, Warty VJ, Starzl TE. Interaction between FK506 and clotrimazole in a liver transplant recipient. *Transplantation* 1991;52:1086–7.
 - [27] Sorrow ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. *Blood* 2005;106:2912–9.
 - [28] Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. *Ann Pharmacother* 2007;41:674–80.